Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 16, 2005

View Archived Issues

CDC recommends Menactra meningococcal vaccine for adolescents, college freshmen

Further monitoring required for Elidel, Protopic postmarketing adverse events

PRO-2000 studied in new NIAID-sponsored international trial

Xinlay NDA accepted for filing

NicOx selected to join EICOSANOX

Abbott and OraSure sign distribution agreement for OraQuick Advance test

Bavarian Nordic to raise capital for new programs

New phase II trial for Gabapentin ER in postherpetic neuralgia

Topline data from STRIDE-2 study in PAH

Sarissa inlicenses antisense drug from Isis

Tripep seeks approval for Thai HIV trial of alpha-HGA

Vanos receives FDA approval

Private financing at Voyager to fund Alzheimer's drug development

FDA COX-2 safety review to explore potential mechanisms of risk

New data on the effects of rosiglitazone on lipid metabolism in type 2 diabetes

Antitumor effects reported for Davanat plus 5-fluorouracil in patients with advanced solid tumors

Darbepoetin alfa improves chemotherapy-induced anemia in patients with gastrointestinal cancers

Antibacterial prodrugs of 6-beta-hydroxymethylpenicillanic acid sulfone claimed in Pfizer patent

Thrombopoietin receptor (TPOR) activators disclosed by Nissan Chemical

Genelabs Technologies presents novel antiviral agents

New 5-HT receptor modulators claimed by Suven Life Sciences

Merck Frosst claims novel inhibitors of leukotriene biosynthesis

New DPP-IV inhibitors for the treatment of NIDDM reported by Fujisawa

Tibolone reduces hot flushes and sweats in tamoxifen-treated breast cancer patients

AMN-107, a novel Bcr-Abl kinase inhibitor for the treatment of CML

Efficacy of the GABA-B receptor agonist CGP-44532 in response to nicotine

New evidence for the involvement of mGluR2/3 in primate cognitive function

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...